Your browser doesn't support javascript.
Clinical study of antibody cocktail therapy for COVID-19
Journal of the Japanese Association for Infectious Diseases ; 96(5):179-185, 2022.
Article in Japanese | GIM | ID: covidwho-2203546
ABSTRACT

Background:

Randomized phase III clinical trials suggest that the antibody cocktail containing casirivimab and imdevimab reduces the risk of hospitalization/death in high-risk COVID-19 patients. However, the efficacy of the cocktail in daily clinical practice remains unknown.
Keywords

Full text: Available Collection: Databases of international organizations Database: GIM Type of study: Prognostic study Language: Japanese Journal: Journal of the Japanese Association for Infectious Diseases Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: GIM Type of study: Prognostic study Language: Japanese Journal: Journal of the Japanese Association for Infectious Diseases Year: 2022 Document Type: Article